Form 8-K - Current report:
SEC Accession No. 0001214659-25-003658
Filing Date
2025-02-28
Accepted
2025-02-28 16:30:27
Documents
17
Period of Report
2025-02-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 z2272508k.htm   iXBRL 8-K 44091
2 EXHIBIT 3.1 ex3_1.htm EX-3.1 120764
3 EXHIBIT 4.1 ex4_1.htm EX-4.1 86197
4 EXHIBIT 10.1 ex10_1.htm EX-10.1 284648
5 EXHIBIT 10.2 ex10_2.htm EX-10.2 165840
  Complete submission text file 0001214659-25-003658.txt   1045387

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE alzn-20250228.xsd EX-101.SCH 2991
7 XBRL LABEL FILE alzn-20250228_lab.xml EX-101.LAB 34240
8 XBRL PRESENTATION FILE alzn-20250228_pre.xml EX-101.PRE 24149
19 EXTRACTED XBRL INSTANCE DOCUMENT z2272508k_htm.xml XML 3926
Mailing Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326
Business Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326 844-722-6333
Alzamend Neuro, Inc. (Filer) CIK: 0001677077 (see all company filings)

EIN.: 811822909 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-40483 | Film No.: 25690895
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)